Person: ŞENTÜRK, HAKAN
7 results
Search Results
Now showing 1 - 7 of 7
Publication Metadata only Early prediction of the severe course, survival, and ICU requirements in acute pancreatitis by artificial intelligence(2023-01-01) İnce A. T.; Silahtaroğlu G.; Seven G.; Koçhan K.; Yıldız K.; Şentürk H.; İNCE, ALİ TÜZÜN; SEVEN, GÜLSEREN; KOÇHAN, KORAY; ŞENTÜRK, HAKANAbstractObjectiveTo evaluate the success of artificial intelligence for early prediction of severe course, survival, and intensive care unit(ICU) requirement in patients with acute pancreatitis(AP).MethodsRetrospectively, 1334 patients were included the study. Severity is determined according to the Revised Atlanta Classification(RAC). The success of machine learning(ML) method was evaluated by 13 simple demographic, clinical, etiologic, and laboratory features obtained on ER admission. Additionally, it was evaluated whether Balthazar-computerized tomography severity index(CTSI) at 48-h contributed to success. The dataset was split into two parts, 90% for ML(of which 70% for learning and 30% for testing) and 10% for validation and 5-fold stratified sampling has been utilized. Variable Importance was used in the selection of features during training phase of machine. The Gradient Boost Algorithm trained the machine by KNIME analytics platform. SMOTE has been applied to increase the minority classes for training. The combined effects of the measured features were examined by multivariate logistic regression analysis and reciever operating curve curves of the prediction and confidence of the target variables were obtained.ResultsAccuracy values for the early estimation of Atlanta severity score, ICU requirement, and survival were found as 88.20%, 98.25%, and 92.77% respectively. When Balthazar-CTSI score is used, results were found as 91.02%, 92.25%, and 98% respectively.ConclusionsThe ML method we used successfully predicted the severe course, ICU requirement and survival, with promising accuracy values of over 88%. If 48-h Balthazar-CTSI is included in the calculation, the severity score and survival rates increase even more.Publication Metadata only Comparison of the optimized direct spectrophotometric serum prolidase enzyme activity assay method with the currently used spectrophotometric assay methods and liver fibrosis indexes to distinguish the early stages of liver fibrosis in patients with chronic hepatitis B infection(2023-04-01) Kayadibi H.; Köker I. H.; Şentürk H.; Merzifonlu S. C.; İnce A. T.; ŞENTÜRK, HAKAN; İNCE, ALİ TÜZÜNPublication Metadata only Comparison of Endoscopic Ultrasound Guided Coil Injectıon with or without cyanoacrylate injection for gastric varices(2022-05-23) Seven G.; Musayeva G.; Seven O. O.; Herdan E.; İnce A. T.; Şentürk H.; SEVEN, GÜLSEREN; İNCE, ALİ TÜZÜN; ŞENTÜRK, HAKANPublication Metadata only The liver-kidney axis: Is serum leptin a potential link in non-alcoholic fatty liver disease-associated chronic kidney disease?(2023-01-01) Canbakan M.; Bakkaloglu O. K.; Atay K.; Koroglu E.; Tuncer M. M.; CANBAKAN İ. B.; ŞENTÜRK H.; ŞENTÜRK, HAKAN© 2023 Pan-Arab Association of GastroenterologyBackground and study aims: Non-alcoholic fatty liver disease (NAFLD) is an independent risk factor for chronic kidney disease (CKD). Previous studies argued that leptin levels increase significantly with the progression of CKD. But the association between leptin and CKD has not been investigated in patients with NAFLD. Therefore, we conducted this study to establish whether increased leptin level is associated with CKD in NAFLD patients. Patients and methods: In our prospective study with a follow up period of six months thirty-five teetotaller biopsy-proven NAFLD patients were divided as groups with mild, versus advanced, fibrosis. Liver fibrosis was also assessed with Fibroscan. Serum leptin levels were measured by radioimmunoassay. For insulin resistance we used the homeostasis model assessment method (HOMA-IR). For the kidney function, we used the abbreviated formula Modification of Diet in Renal Disease (MDRD) formula, which estimates GFR. For statistical analysis, Student\"s-t test, Mann-Whitney test, linear regression-binary logistic regression analyses and the ROC curve analysis were used. Results: Advanced fibrosis and increased HOMA-IR were risk factors for decreased eGFR. Leptin correlated inversely with advanced fibrosis (p: 0.03) and low leptin was a risk factor for CKD (p: 0.02). In ROC curve analysis, advanced fibrosis and low leptin were risk factors for decreased eGFR (p: 0.007 and 0.004, respectively). Low leptin level was dependently associated with decreased eGFR. Conclusion: Advanced fibrosis in NAFLD patients is a risk factor for CKD. Leptin correlated inversely with advanced fibrosis. Unlike the previous studies, which were not performed in NAFLD patients, we found decreased leptin in NAFLD patients with decreased eGFR. Low leptin level was found to be a dependent predictor for differentiating NAFLD patients with high risk for CKD.Publication Metadata only Ampulla Vateri Tümörlerinde Endoskopik Rezeksiyon: Tek Merkezden 62 Hastanın Uzun Dönem Sonuçları(2022-11-22) Koçhan K.; Biberci Keskin E.; Şentürk H.; KOÇHAN, KORAY; BİBERCİ KESKİN, ELMAS; ŞENTÜRK, HAKANPublication Metadata only Gut bacteria after recovery from COVID-19: a pilot study(2022-01-01) Polo P. G.; AL B. Ç.; ŞENTÜRK H.; RAFIQI A. M.; AL, BİRGÜL ÇOLAK; ŞENTÜRK, HAKAN; RAFIQI, ABDUL MATTEENOBJECTIVE: COVID-19 has been a major infectious disease lately in hu-mans. 10% of people experience persistent symptoms twelve weeks after having COVID-19. The gut microbiota is essential for host immunity. Thus, gut microbiota composition may contribute to the recovery of COVID-19 patients. The impact of COVID-19 on the gut microbiota of patients during recovery is less explored. We investigated the potential alterations of bacterial gut microbiota of immediately recovered COVID-19 patients, and six months after their recovery. MATERIALS AND METHODS: Stool samples were collected from 8 patients with COVID-19 immediately after their recovery, and six months after SARS-CoV-2 clearance, as well as from 8 healthy donors as a control group. 16S rRNA gene sequencing was performed to analyze the correlation between disease recovery and microbiota using the immediately recovered and control group. Specific primers were designed for the most significantly altered bacteria and used to analyze the changes in intestinal mi-crobiota composition of patients using qPCR. qPCR comparisons were performed on three groups: newly recovered from COVID-19, after six months of COVID-19 recovery, and healthy controls.RESULTS: Compared with the healthy con-trol group, patients who immediately recovered from COVID-19 had significantly less presence of 15 bacterial groups. The immediately recovered patients had a very significantly higher relative abundance of the opportunistic pathogen Mycolicibacterium. No differences were found between the immediately recovered patients, and after six months of recovery using the qP-CR analyses.CONCLUSIONS: Our results contribute novel insights regarding the alteration of human gut microbiota and the emergence of opportunistic pathogens in recovered patients of COVID-19. Further studies with a larger experimental size are needed to reveal balance or dysbiosis in patients after COVID-19 recovery.Publication Metadata only Results of nucleos(t)ide analog treatment discontinuation in hepatitis b e-Antigen-negative chronic hepatitis b: Nucstop study(2024-01-01) Kiremitci S.; Kochan K.; SEVEN G.; Keskin E. B.; OKAY G.; AKKOYUNLU Y.; Koc M. M.; SÜMBÜL B.; ŞENTÜRK H.; KİREMİTÇİ, SERCAN; KOÇHAN, KORAY; SEVEN, GÜLSEREN; OKAY, GÜLAY; AKKOYUNLU, YASEMİN; SÜMBÜL, BİLGE; ŞENTÜRK, HAKANBackground/Aims: This study aims to investigate the effects of nucleos(t)ide analogs (NAs) discontinuation in eligible patients in accordance with the Asian Pacific Association for the Study of the Liver hepatitis B guideline and the factors affecting clinical and virological relapses. Materials and Methods: In this prospectively designed study, hepatitis B e antigen (HBeAg)-negative chronic hepatitis B patients who were followed up between 2012 and 2019 were evaluated and 57 patients were included. All participants enrolled the study were HBeAgnegative status at NA initiation. Results: The median age of the patients was 49 (29-72) years and 24 (42%) were females. The median treatment duration was 96 (36-276) months and patients were followed for a median duration of 27 months. Sixteen patients had a previous history of NA switch, and thirteen of these patients had a history of lamivudine resistance. Thirty-eight of 57 patients (66%) developed an elevated hepatitis B virus deoxyribonucleic acid level of 2000 IU/mL at least once, defined as virological relapse and 23 (60%) of them, experienced clinical relapse. Thirty-one of 57 patients were re-Treated during the follow-up, and hepatitis B surface antigen (HBsAg) loss occurred among 4 (7%) patients. All patients who experienced HBsAg loss had a history of lamivudine resistance (P = .002). Conclusion: Despite receiving NAs suppression therapy for a long time, HBsAg loss occurs rarely. Although it was not life-Threatening, most patients experienced relapses and treatment should be restarted. In our study, whether it is a coincidence that all patients with HBsAg loss are patients in whom NAs are used sequentially due to lamivudine resistance is an issue that needs to be further investigated.